Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | TSPO | P30536 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405714 | 0.93 | ALOX5 (0.47) | MAOBALOX5TSPOPTGS1PTGS2 | |
| SCHEMBL6404636 | 0.86 | KMT2A (0.44) | TSPOMEN1KMT2A | |
| SCHEMBL8027772 | 0.86 | TSPO (0.53) | ALOX5TSPOMEN1KMT2APTGS1 | |
| SCHEMBL8041211 | 0.85 | FFAR1 (0.44) | MAOBTSPOHIF1A | |
| SCHEMBL8037973 | 0.84 | CNR1 (0.43) | MAOBMEN1KMT2AHIF1AMAOA | |
| SCHEMBL8027787 | 0.84 | MRGPRX4 (0.46) | MAOBTSPOKMT2AHIF1AMAOA | |
| SCHEMBL8044225 | 0.84 | ALOX5 (0.45) | MAOBALOX5TSPOPTGS1PTGS2 | |
| SCHEMBL6408806 | 0.83 | ALOX5 (0.50) | MAOBALOX5TSPOPTGS1PTGS2 | |
| SCHEMBL8037899 | 0.82 | MAPT (0.51) | TSPOKMT2AALDH1A1 | |
| SCHEMBL6403207 | 0.81 | TSPO (0.45) | TSPOMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1245380-C | Anthranilic acid derivatives | TEIJIN LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| US-6890932-B2 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| EP-1101755-B1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| US-6649656-B1 | Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents | TEIJIN LIMITED (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-1101755-A1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | MAOB 1744/4885ALOX5 403/4885TSPO 769/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | MAOB 1070/4885ALOX5 324/4885TSPO 678/4885 |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | IGLV6-57, FCGRT, IGSF11 | MAOB 2681/4885ALOX5 620/4885TSPO 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.